There is interindividual variation in lipid-lowering response to statins. The objective of this study was to investigate whether common variation in genes involved in lipid and statin metabolism modify the effect of statins on serum total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein-cholesterol concentration in coronary artery disease (CAD) patients. We studied the association between 18 single-nucleotide polymorphisms (SNPs) in six genes (HMGCR, CETP, APOAI, ABCB1, CYP3A4, CYP7A1) in response to atorvastatin therapy (20 mg/day) in 265 newly diagnosed CAD patients using multivariable adjusted general linear regression. Variant alleles of ABCB1 (-41A/G), HMGCR SNP29 G/T, rs5908A/G, rs12916C/T, and CYP7A1-204A/C polymorphisms were significantly associated with attenuated LDL-C reduction and variant alleles of CETP TaqI, -629C/A, and APOAI PstI polymorphisms were associated with higher increase in high-density lipoprotein-cholesterol. A three-loci interaction model consisting of CYP7A1rs892871AA/APOAIPstIP1P1/HMGCR rs12916CT was a better predictor for LDL-C lowering, when compared with single polymorphisms analysis on statin response. Variant genotypes of APOAI −2500C/T, CETP 405I/V, and ABCB1 3435C/T showed higher risk of myocardial infarction events (p < 0.05) in a 1-year follow-up of CAD patients. These results suggest that SNPs in lipid and statin pathway genes are associated with reduced LDL-C lowering by statins and identify individuals who may be resistant to maximal LDL-C lowering by statins.
Get full access to this article
View all access options for this article.
References
1.
AnagnostopoulouK., KolovouG., KostakouP., MihasC., MikhailidisD., CokkinosD.V. 2007. Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects. Expert Opin Pharmacother, 8:2459–2463.
2.
BeckerM.L., VisserL.E., van SchaikR.H., HofmanA., UitterlindenA.G., StrickerB.H.2010. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol Drug Saf, 1:75–81.
3.
CavalliS.A., HirataM.A., HirataR.D.C.2001. Detection of MboII polymorphism at the 5* promoter region of CYP3A4. Clin Chem, 47:348–351.
4.
ChasmanD.I., PosadaD., SubrahmanyanL., CookN.R., StantonV.P.Jr., RidkerP.M.2004. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA, 291:2821–3227.
5.
CoutureP., OtvosJ.D., CupplesL.A., WilsonP.W., SchaeferE.J., OrdovasJ.M.1999. Association of the A–204C polymorphism in the cholesterol 7_- hydroxylase gene with variations in plasma low density lipoprotein cholesterol levels in the Framingham Offspring Study. J Lipid Res, 40:1883–1889.
6.
Dallinga-ThieG.M., BuX.D., van Linde-Sibenius TripM., RotterJ.I., LusisA.J., de BruinW.A.1996. Apolipoprotein A-I/C4 WA-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-Ill. J Lipid Res, 37:136–147.
7.
EiriksdottirG., BollaM.K., ThorssonB., SigurdssonG., HumphriesS.E., GudnasonV.2001. The -629C-A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men. Atherosclerosis, 159:187–192.
8.
FiegenbaumM., da SilveiraF.R., van der SandC.R., van der SandL.C., FerreiraM.E., PiresR.C., HutzM.H.2005. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther, 78:551–558.
9.
GaoY., ZhangL.R., FuQ.2008. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol, 9:877–882.
10.
GordonD., FinchS.J., NothnagelM., OttJ.2002. Power and sample size calculations for case-control genetic association tests when errors present: application to single nucleotide polymorphisms. Hum Hered, 54:22–33.
11.
GordonD., LevenstienM.A., FinchS.J., OttJ.2003. Errors and linkage disequilibrium interact multiplicatively when computing sample sizes for genetic case-control association studies. Pacific Symposium on Biocomputing, 490–501. http://psb.stanford.edu/psbonline/proceedings/psb03/.
12.
GoulasA., KosmidouM., HatzitoliosA.I., MolyvaD., FidaniL., GiannopoulosS., MirtsouV.2008. Glutathione S-transferase null and cholesteryl ester transfer protein TaqI B polymorphisms and lipid response to atorvastatin in Greek dyslipidaemic patients. Basic Clin Pharmacol Toxicol, 6:559–562.
13.
HindorffL.A., LemaitreaR.N., SmithN.L., BisJ.C., MarcianteK.D., RiceK.M., LumleyT., EnquobahrieD.A., LiG., HeckbertS.R., PsatyB.M.2008. Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke. Pharmacogen Genomics, 18:677–682.
14.
HutzM.H., FiegenbaumM.2008. Impact of genetic polymorphisms on the efficacy of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs, 8:161–170.
15.
IsaacsA., Sayed-TabatabaeiaF.A., HofmanA., OostraB.A., KlungelO.H., MaitlandVander ZeeA.H., StrickerB.H., WittemanJ.C., van DuijnC.M.2007. The cholesteryl ester transfer protein I405V polymorphism is associated with increased high-density lipoprotein levels and decreased risk of myocardial infarction: the Rotterdam Study. Eur J Cardiovasc Prev Rehabil, 14:419–421.
16.
KajinamiK., BrousseauM.E., OrdovasJ.M., SchaeferE.J.2004a. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol, 93:104–107.
17.
KajinamiK., BrousseauM.E., OrdovasJ.M., SchaeferE.J.2004b. Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. Atherosclerosis, 175:287–293.
18.
KajinamiK., BrousseauM.E., OrdovasJ.M., SchaeferE.J.2004c. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol, 93:1046–1050.
KambohM.I., AstonC.E., NestlerodeC.M., McAllisterA.E., HammanR.F.1996. Haplotype analysis of two APOA1/MspI polymorphisms in relation to plasma levels of apo A-I and HDL-cholesterol. Atherosclerosis, 127:255–262.
21.
KlerkxA.H., de GroothG.J., ZwindermanA.H., JukemaJ.W., KuivenhovenJ.A., KasteleinJ.J.2004. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS)Eur J Clin Invest, 1:21–28.
22.
KondoI., BergK., DraynaD.T., LawnR.M.1989. DNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoprotein cholesterol and apolipoprotein concentrations. Clin Genet, 35:49–56.
23.
KuivenhovenJ.A., JukemaJ.W., ZwindermanA.H., de KnijffP., McPhersonR., BruschkeA.V., LieK.I., KasteleinJ.J.1998. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med, 2:86–93.
24.
LahiriD.K., NurnbergerJ.L.Jr.1991. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acid Res, 19:5444.
25.
LahozC., PenaR., MostazaJ.M., JiménezJ., SubiratsE., PintóX., TaboadaM., López-PastorA. RAP Study Group. 2003. Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy. Atherosclerosis, 168:289–295.
26.
LaRosaJ.C.2000. Statins and risk of coronary heart disease. JAMA, 283:2935–2936.
27.
LeeS., BellD.A., CoulterS.J., GhanayemB., GoldsteinJ.A.2005. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther, 131:302–309.
28.
Maitland-van der ZeeA.H., KlungelO.H., StrickerB.H., Monique VerschurenW.M., KasteleinJ.J., LeufkensH.G., de BoerA.2002. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis, 163:213–222.
29.
MangraviteL.M., ThornC.F., KraussR.M.2006. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J, 6:360–374.
30.
MasanaL., FebrerG., CavannaJ., BaroniM.G., MarzW., HoffmannM.M., ShineB., GaltonD.J.2001. Common genetic variants that relate to disorders of lipid transport in Spanish subjects with premature coronary artery disease. Clin Sci, 100:183–190.
31.
MohrschladtM.F., van der Sman-de BeerF., HofmanM.K., van der KrabbenM., WestendorpR.G., SmeltA.H.2005. TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia. Eur J Hum Genet, 7:877–882.
32.
[NCEP] Third report of the National Cholesterol Education Program. 2002. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final ReportU.S. Department of Health and Human Services; Public Health Service; National Institutes of Health; National Heart, Lung and Blood Institute. NIH Publication No. 02–5215 National Institutes of Health, Bethesda, Maryland.
33.
PadmajaN., KumarR.M., SoyaS.S., AdithanC.2007. Common variants of cholesteryl ester transfer protein gene and their association with lipid parameters in healthy volunteers of Tamilian population. Clin Chim Acta, 375:140–146.
34.
PoduriA., KhullarM., BahlA., SharmaY.P., TalwarK.K.2009. A combination of proatherogenic single-nucleotide polymorphisms is associated with increased risk of coronary artery disease and myocardial infarction in Asian Indians. DNA Cell Biol, 28:451–460.
35.
PuccettiL., AcampaM., AuteriA.2007. Pharmacogenetics of statin therapy. Recent Pat Cardiovasc Drug Discov, 2:228–236.
36.
RodriguesA.C., RebecchiI.M., BertolamiM.C., FaludiA.A., HirataM.H., HirataR.D.2005. High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. Braz J Med Biol Res, 38:1389–1397.
37.
SchmitzG., Schmitz-MadryA., UgocsaiP.2007. Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Curr Opin Lipidol, 18:164–173.
38.
SorkinS.C., ForestieroF.J., HirataM.H., GuzmánE.C., CavalliS.A., BertolamiM.C., SalazarL.A., HirataR.D.2005. APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals. Clin Chem Lab Med, 12:1339–1345.
39.
TanabeM., IeiriI., NagataN., InoueK., ItoS., KanamoriY., TakahashiM., KurataY., KigawaJ., HiguchiS., TerakawaN., OtsuboK.2001. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther, 297:1147–1153.
40.
ThompsonJ.F., ManM., JohnsonK.J., WoodL.S., LiraM.E., LloydD.B., BanerjeeP., MilosP.M., MyrandS.P., PaulauskisJ., MiladM.A., SasielaW.J.2005. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J, 5:352–358.
41.
VavatsiN.A., KouidouS.A., GelerisP.N., TachmatzidisC., GikasT., TsifodimosD.K., TrakatellisA.C.1995. Increased frequency of the rare PstI allele (P2) in a population of CAD patients in northern Greece. Clin Genet, 47:22–26.
42.
WangJ., FreemanD.J., GrundyS.M., LevineD.M., GuerraR., CohenJ.C.1998. Linkage between cholesterol 7alphahydroxylase and high plasma low-density lipoprotein cholesterol concentrations. J Clin Invest, 101:1283–1291.
43.
WilkeR.A., MooreJ.H., BurmesterJ.K.2005. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics, 6:415–421.
44.
WuJ.H., LeeY.T., HsuH.C., HseihL.L.2001. Influence of CETP gene variation on plasma lipid concentrations and coronary heart disease: a survey in Taiwan. Atherosclerosis, 159:451–458.
45.
YanoJ.K., WesterM.R., SchochG.A., GriffinK.J., StoutC.D., JohnsonE.F.2004. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-Å resolution. J Biol Chem, 279:38091–38094.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
